Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Int J Mol Sci. 2024 Mar 5;25(5):3011. doi: 10.3390/ijms25053011.
Extracorporeal photopheresis (ECP) is an apheresis procedure that is conventionally used as a first-line treatment for cutaneous and leukemic subtypes of T-cell lymphoma, such as Sezary's syndrome and mycosis fungoides. Over the past three decades, its immunotherapeutic properties have been tested on a variety of autoimmune conditions, including many dermatologic diseases. There is ample evidence of ECP's ability to modify leukocytes and alter cytokine production for certain dermatologic diseases that have been refractory to first-line treatments, such as atopic dermatitis. However, the evidence on the efficacy of ECP for the treatment of these dermatologic diseases is unclear and/or lacks sufficient evidence. The purpose of this paper is to review the literature on the utilization and clinical efficacy of ECP in the treatment of several [autoimmune] dermatologic diseases and discuss its applications, guidelines, recommendations, and future implementation for dermatologic diseases.
体外光分离术（ECP）是一种血液分离程序，通常用作皮肤和白血病 T 细胞淋巴瘤亚型的一线治疗方法，例如蕈样真菌病和 Sezary 综合征。在过去的三十年中，其免疫治疗特性已在多种自身免疫性疾病中进行了测试，包括许多皮肤病。有充分的证据表明，ECP 能够改变白细胞并改变细胞因子的产生，从而治疗某些对一线治疗方法（例如特应性皮炎）有抗药性的皮肤病。但是，关于 ECP 治疗这些皮肤病的疗效的证据尚不清楚和/或缺乏足够的证据。本文的目的是回顾有关 ECP 在几种[自身免疫性]皮肤病治疗中的应用和临床疗效的文献，并讨论其在皮肤病中的应用，指南，建议和未来的实施。
